Redox processes in neurodegenerative disease involving reactive oxygen species

Current Neuropharmacology

Volumn 10, Issue 4, 2012, Pages 289-302

  Kovacic, Peter ^a   Somanathan, Ratnasamy ^b  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b TIJUANA INSTITUTE OF TECHNOLOGY   (Mexico)

Author keywords

Neurodegenerative diseases; Oxidative stress; Reactive oxygen species; Redox

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; COPPER; GLUTATHIONE; IDEBRENONE; IRON; LITHIUM CARBONATE; MELATONIN; NEU 2000; NITRIC OXIDE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SELENIUM; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ATAXIA; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; DOWN SYNDROME; ELECTROSTIMULATION; EMOTIONAL STRESS; EPILEPSY; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PRION DISEASE; REVIEW; TARDIVE DYSKINESIA;

EID: 84874860528     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912804499429     Document Type: Review

References (219)

1. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem., 2006, 97, 1634-1658.
2. Kovacic, P. Novel electrochemical approach to enhanced toxicitry of 4-oxo-2-nonenal vs. 4-hydroxy-2-nonenal (role of imine): oxidative stress and therapeutic modalities. Med. Hypotheses, 2006, 67, 151-156.
3. Min, K. J.; Yang, M. S.; Kim, S. U.; Joe, E. H. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J. Neurosci., 2006, 26, 1880-1887.
4. Chiu, D. T.; van den Berg, J.; Kuypers, F. A.; Hung, I-J.; Wei, J-S.; Liu, T-Z. Correlation of membrane lipid peroxidation with oxidation of hemoglobin variants: possibly related to the rates of hemin release. Free Radic. Biol. Med., 1996, 21, 89-95.
5. Kovacic, P.; Somanathan, R. Nervous about developments in electron transfer-ROS-oxidative stress: mechanisms of neurotoxicity? In Systems Biology of Free Radicals and Antioxidants, Laher, J, ed., Springer Verlag, New York, 2012, in press.
6. Kovacic, P.; Somanathan, R. Neurotoxicity: the broad framework of electron transfer, oxidative stress and protection by antioxidants. Curr. Med. Chem.-CNS Agents, 2005, 5, 249-258.
7. Jacintho, J. D.; Kovacic, P. Neurotransmission and neurotoxicity by nitric oxide, catecholamines, and glutamate: unifying themes of reactive oxygen species and electron transfer. Curr. Med. Chem., 2003, 10, 2693-2703.
8. Halliwell, B., Gutteridge, J. M. C. Free Radicals in Biology and Medicine. Oxford University Press, 1999, a) p. 727, b) p. 171, 755, c) p. 693, 700, 758, 759, d) p. 755-756, e) p. 618, 619, 757, f) p. 760-761, g) p. 751, h) p. 759-760.
9. Medina-Ceja, L.; Guerrero-Cazares, H.; Canales-Aguirre, A.; Morales-Villagran, A.; Feria-Velasco, A. Structural and functional characteristics of glutamate transporters: how they are related to epilepsy and oxidative stress. Rev. Neurol., 2007, 45, 341-352.
10. Tupeev, I. R.; Kryzhanovskiǐ, G. N.; Nikushkin, E. V.; Bordiukov, M. M.; Luzefova, S. M. The antioxidant system in the dynamic combined treatment of epilepsy patient with traditional anticonvulsant preparations and an antioxidant0alpha-tocopherol. Biull. Eksp. Biol. Med., 1993, 116, 362-364.
11. Sołowiej, E.; Sobaniec, W. The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy. Neurol. Neurochir. Pol., 2003, 37, 991-1003.
12. Gusakov, I. V.; Sharonov, B. P.; Oparina, T. I.; Kambarova, D. K. The effect of superoxide dismutase on seizures in an experimental rat model of epilepsy. Biull. Eksp. Biol. Med., 1995, 120, 20-22.
13. Ashrafi, M. R.; Shams, S.; Nouri, M.; Moheni, M.; Shabanian, R.; Yekaninejad, M. S.; Chegini, N.; Khodadad, A.; Safaralizadeh, R. A probable causative factor for an old problem: selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia, 2007, 48, 1750-1755.
14. 3-induced epilepsy. Free Radic. Biol. Med., 1990, 9, 451-454.
15. Sobaniec, H.; Sobaniec, W.; Sendrowski, K.; Sobaniec, S.; Pietruska, M. Antioxidant activity of blood serum and saliva in patients with periodontal disease treated due to epilepsy. Adv. Med. Sci., 2007, 52, 204-206.
16. Gluck, M.R.; Jayatilleke, E.; Shaw, S.; Rowan, A. J.; Haroutunian, V. CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res., 2000, 39, 63-71.
17. Azam, F.; El-Gnidi, B. A.; Alkskas, I. A. Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(napthalen-1-yl)semicarbazides. Eur. J. Med. Chem., 2010, 45, 2817-2826.
18. Lehtinen, M. K.; Tegelberg, S.; Schipper, H.; Su, H.; Zukor, H.; Manninen, O.; Kopra, O.; Joensuu, T.; Hakala, P.; Bonni, A.; Lehesjoki, A. E. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J. Neurosci., 2009, 29, 5910-5915.
19. Swamy, M.; Yusof, W. R.; Sirajudeen, K. N.; Mustapha, Z.; Govindasamy, C. Decreased glutamine synthetase, increased citrulline-nitric oxide cycle activities, and oxidative stress in different regions of brain in epilepsy rat model. J. Physiol. Biochem., 2010, 67, 105-113.
20. Willmore, L. J.; Triggs, W. J. Effect of phenytoin and corticosteroids on seizures and lipid peroxidation in experimental posttraumatic epilepsy. J. Neurosurg., 1984, 60, 467-472.
21. Gupta, M.; Gupta, Y. K.; Agarwal, S.; Aneja, S.; Kalaivani, M.; Kohli, K. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized double-blind, placebocontrolled trial. Epilepsia, 2004, 45, 1636-1639.
22. Arhan, E.; Serdaroglu, A.; Ozturk, B.; Ozturk, H. S.; Ozcelik, A.; Kurt, N.; Kutsal, E.; Sevinc, N. Effects of epilepsy and antiepileptic drugs on nitric oxide, lipid peroxidation and xanthine oxidase system in children with idiopathic epilepsy. Seizure, 2011, 20, 138-142.
23. Frantseva, M. V.; Velazquez, J. L.; Hwang, P. A.; Carlen, P. L. Free radical production correlates with cell death in an in vitro model of epilepsy. Eur. J. Neurosci., 2000, 12, 1431-1439.
24. Pahuja, M.; Mehla, J.; Reeta, K. H.; Joshi, S.; Gupta, Y. K. Hydroalcoholic extract of Zizyphus jujube ameliorates seizures, oxidative stress, and cognitive impairment in experimental models of epilepsy in rats. Epilepsy Behav., 2011, 21, 356-363.
25. Ounjaijean, S.; Westermarck, T.; Partinen, M.; Plonka-Poltorak, E.; Kaipainen, P.; Kaski, M.; Fucharoen, S.; Srichairatanakool, S.; Atroshi, F. Increase in non-transferrin bound iron and the oxidative stress status in epilepsy patients treated using valproic acid monotherapy. Int. J. Clin. Pharmacol. Ther., 2011, 49, 268-276.
26. Freitas, R. M. Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci. Lett., 2009, 462, 225-229.
27. Turkdogan, D.; Toplan, S.; Karakoc, Y. Lipid peroxidation and antioxidative enzyme activities in childhood epilepsy. J. Child Neurol., 2002, 17, 673-676.
28. Deepa, D.; Jayakumari, B.; Thomas, S. V. Lipid peroxidation in women with epilepsy. Ann. Indian Acad. Neurol., 2008, 11, 44-46.
29. Waldbaum, S.; Patel, M. Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res., 2010, 88, 23-45.
30. Chuang Y-C. Mitochondrial dysfunction and oxidative stress in seizure-induced neuronal cell death. Acta Neurol. Taiwan, 2010, 19, 3-15
31. Waldbaum, S.; Patel, M. Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy? J. Bioenerg. Biomembr., 2010, 42, 449-455.
32. Patel, M. N. Oxidative stress, mitochondrial dysfunction, and epilepsy. Free Rad. Res., 2002, 36, 1139-1146.
33. Costello, D. J.; Delanty, N. Oxidative injury in epilepsy: potential for antioxidant therapy? Expert Rev. Neurother., 2004, 4, 541-553.
34. Sudha, K.; Rao, A. V, Rao, A. Oxidative stress and antioxidants in epilepsy. Clin. Chim. Acta., 2001, 303, 19-24.
35. Frantseva, M. V.; Perez Velazquez, J. L.; Tsoraklidis, G.; Mendonca, A. J.; Adamhik, Y.; Mills, L. R.; Carlen, O. L.; Burnham, M. W. Oxidative stress is involved in seizure-induced neurodegeneration in the kindling model of epilepsy. Neuroscience, 2000, 97, 431-535.
36. Pestana, R. R.; Kinjo, E. R.; Hernandes, M. S.; Britto, L. R. Reactive oxygen species generated by NADPH oxidase are involved in neurodegeneration in the pilocarpine model of temporal lobe epilepsy. Neurosci. Lett., 2010, 484, 187-191.
37. Lores Arnaiz, S.; Travacio, M.; Llesuy, S.; Rodriguez de Lores Arnaiz, G. Regional vulnerability to oxidative stress in a model of experimental epilepsy. Neurochem. Res., 1998, 23, 1477-1483.
38. Naziroglu, M. Role of selenium on calcium signaling and oxidative stress-induced molecular pathways in epilepsy. Neurochem. Res., 2009, 34, 2181-2191.
39. Mori, N.; Yokoyama, H. (1993) Role of superoxide dismutase in a kindling model of epilepsy. Comp. Biochem. Physiol. C, 1993, 104, 373-376.
40. Peternel, S.; Pilipović, K.; Zupan, G. Seizures susceptibility and the brain regional sensitivity to oxidative stress in male and female rats in the lithium-pilocarpine model of temporal lobe epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 456-462.
41. Ezz, H. S.; Kharawy, Y. A.; Noor, N. A. The neuroprotective effect of cuccumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochem. Res., 2011, 36, 2195-2204.
42. Medvedev, A. E.; Rajgorodskaya, D. I.; Gorkin, V. Z.; Fedotova, I. B.; Semiokhina, A. F. The role of lipid peroxidation in the possible involvement of membrane-bound monamine oxidases in gammaaminobutyric acid and glucosamine deamination in rat brain. Focus on chemical pathogenesis of experimental audiogenic epilepsy. Mol. Chem. Neuropathol., 1992, 16, 187-201.
43. Chakrabarti, L.; Galdzicki, Z.; Haydar, T. Defect in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci., 2007, 27, 11483-11495.
44. Zambranco, J. C.; Marquina, R.; Sulbarán, N.; Rodríguez-Malaver, A. J.; Reyes, R. A. Aerobic exercise reduced oxidative stress in saliva of persons with Down syndrome. Res. Sports Med., 2009, 17, 195-203.
45. Gulesserian, T.; Engidawork, E.; Fountoulakis, M.; Lubec, G. Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J. Neural. Transm. Suppl., 2001, 61, 71-84.
46. Cengiz, M.; Seven, M.; Suyugül, N. Antioxidant system in Down syndrome: a possible role in cataractogenesis. Genetic Counseling, 2002, 13, 339-342.
47. Lott, I. T.; Head, E.; Doran, E.; Busciglio, J. Beta-amyloid, oxidative stress and Down syndrome. Curr. Alzheimer Res., 2006, 3, 521-528.
48. Tórsdóttir, G.; Kristinsson, J.; Hreidarsson, S.; Snaedal, J.; Jóhannesson, T. Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome. Pharmacol. Toxicol., 2001, 89, 320-325.
49. Lorenzo, L. P.; Chen, H.; Shatynski, K. E.; Clark, S.; Yuan, R.; Harrison, D. E.; Yarowsky, P. J.; Williams, M. S. Defective hematopoietic stem cell and lymphoid progenitor development in the Ts65Dn mouse model of Down syndrome: potential role of oxidative stress. Antioxid. Redox. Signal, 2011, 15, 2083-2094.
50. Lott, I. T.; Doran, E.; Nguyen, V. Q.; Tournay, A.; Head, E.; Gillen, D. L. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am. J. Med. Genet. A, 2011, 155A, 1939-1948.
51. Perrone, S.; Longini, M.; Bellieni, C. V.; Centini, G.; Kenanidis, A.; De Marco, L.; Petraglia, F.; Buonocore, G. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin. Biochem., 2006, 40, 177-180.
52. Sebastiá, J.; Cristófol, R.; Pertusa, M.; Vílchez, D.; Torán, N.; Barambio, S.; Rodríguez-Farré, E.; Sanfeliu, C. Down's syndrome astrocytes have greater antioxidant capacity than euploid astrocytes. Eur. J. Neurosci., 2004, 20, 2355-2366.
53. Lee, M.; Hyun, D.; Jenner, P.; Halliwell, B. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defenses: relevance to Down's syndrome and familial amyotrophic sclerosis. J. Neurochem., 2001, 76, 957-965.
54. 2-induced apoptosis: implications for Down's syndrome. Biochem. Biophys. Res. Commun., 2001, 287, 1003-1008.
55. Capone, G.; Kim, P.; Jovanovich, S.; Payne, L.; Freund, L.; Welch, K.; Miller, E.; Trush, M. Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci., 2002, 70, 2885-2895.
56. Pastore, A.; Tozzi, G.; Gaeta, L. M.; Giannotti, A.; Bertini, E.; Federici, G.; Digilio, M. C.; Piemonte, F. Glutathione metabolism and antioxidant enzymes in children with Down syndrome. J. Pediatr., 2003,142, 583-585.
57. Meguid, N. A.; Dardir, A. A.; El-Sayed, E. M.; Ahmed, H. H.; Hashish, A. F.; Ezzat, A. Homocysteine and oxidative stress in Egyptian children with Down syndrome. Clin. Biochem., 2010, 43, 963-967.
58. Schuchmann, S.; Heinemann, U. Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. Free Radic. Biol. Med., 2000, 28, 235-250.
59. Muchová, J.; Sustrová, M.; Garaiová, I.; Liptáková, A.; Blazícek, P.; Kvasnicka, P.; Pueschel, S.; Duracková, Z. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes of Down syndrome patients. Free Radic. Biol. Med., 2001, 31, 499-508.
60. Pinto, M.; Neve, J.; Palha, M.; Bicho, M. Oxidative stress in Portugese children with Down syndrome. Down Syndr. Res. Pract., 2002, 8, 79-82.
61. Zitnanová, I.; Korytár, P.; Sobotová, H.; Horáková, L.; Sustrová, M.; Pueschel, S.; Duracková, Z. Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome. Clin. Chem. Lab. Med., 2006, 44, 306-310.
62. Pallardó, F. V.; Lloret, A.; Lebel, M.; d'Ischia, M.; Cogger, V. C.; Le Couteur, D. G.; Gadaleta, M. N.; Castello, G.; Pagano, G. Mitochondrial dysfunction in some oxidative stress-related disease: Ataxia-Telengiectasia, Down syndrome, Fanconi anaemia and Werner syndrome. Biogerontology, 2010,11, 401-419.
63. Nunomura, A.; Perry, G.; Pappolla, M. A.; Friedland, R. P.; Hirai, K.; Chiba, S.; Smith, M. A. Neuronal oxidative stress amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol., 2000, 59, 1011-1017.
64. Strydom, A.; Dickinson, M. J.; Shemde, S.; Pratico, D.; Walker, Z. Oxidative stress and cognitive ability in adults with Down syndrome. Prog. Neuropsychopharmaol. Biol. Psychiatry, 2009, 33, 76-80.
65. Garcez, M. E.; Peres, W.; Salvador, M. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin. Proc., 2005, 80, 1607-1611.
66. Perlugi, M.; di Domenico, F.; Fiorini, A.; Cocciolo, A.; Giorgi, A.; Foppoli, C.; Butterfield, D. A.; Giorlandino, M.; Giolandino, C.; Schininá, M. E.; Coccia, R. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl., 2011, 5, 167-178.
67. Zana, M.; Janka, Z.; Kálman, J. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging, 2007, 28, 648-676.
68. Sánchez-Font, M. F.; Sebastiá, J.; Sanfeliu, C.; Cristófol, R.; Marfany, G.; González-Duarte, R. Peroxidedoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. Cell Mol. Life Sci., 2003, 60, 1513-1523.
69. Carratelli, M.; Porcaro, L.; Ruscica, M.; De Simone, E.; Bertelli, A. A.; Corsi, M. M. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int. J. Clin. Pharmacol. Res., 2001, 21, 79-84.
70. Komatsu, T.; Lee, M. C.; Miyagi, A.; Shoji, H.; Yoshino, F.; Maehata, Y.; Maetani, T.; Kawamura, Y.; Ikeda, M.; Kubota, E. Reactive oxygen species generation in gingival fibroblast of Down syndrome patients detected by electron spin resonance spectroscopy. Redox. Rep., 2006, 11, 71-77.
71. Kanavin, O. J.; Aaseth, J.; Birkrtvedt, G. S. Thyroid hypofunction in Down's syndrome: is it related to oxidative stress? Biol. Trace Elem. Res., 2000, 78, 35-42.
72. Zitnanová, I.; Korytár, P.; Aruoma, O. I.; Sustová, M.; Garaiová, I.; Muchová, J.; Kalnovicová, T.; Pueschel, S.; Duracková, Z. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin. Chim. Acta., 2004, 341, 139-146.
73. Campos, C.; Guzmán, R.; López-Fernández, E.; Casado, A. Urinary uric acid and antioxidant capacity in children and adults with Down syndrome. Clin. Biochem., 2010, 43, 228-233.
74. Jauslin, M. L.; Wirth, T.; Meier, T.; Schoumacher, F. A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum. Mol. Genet., 2002, 11, 3055-3063.
75. Tozzi, G.; Nuccetelli, M.; Lo bello, M.; Bernardini, S.; Bellincampi, L.; Ballerini, S.; Gaeta, L. M.; Casali, C.; Pastore, A.; Federici, G.; Betrtini, E.; Piemonte, F. Antioxidant enzymes in blood of patients with Friedreich's ataxia. Arch. Dis. Child, 2002, 86, 376-379.
76. Aksoy, Y.; Sanal, O.; Metin, A.; Tezcan, I.; Ersoy, F.; Oǧüş, H.; Ozer, N. Antioxidant enzymes in blood cells and lymphocytes of ataxia-telangiectasia patients. Turk. J. Pediatr., 2004, 46, 204-207.
77. Lodi, R.; Hart, P. E.; Rajagopalan, B.; Taylor, D. J.; Crilley, J. G.; Bradley, J. L.; Blamire, A. M.; Manners, D.; Styles, P.; Schapira, A. H.; Sooper, J. M. Antioxidant treatment improves in vivo cardiac skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol., 2001, 49, 590-596.
78. Hart, P. E.; Lodi, R.; Rajagopalanm B.; Bradley, J. L.; Crilley, J. G.; Turner, C.; Blamire, A. M.; Manners, D.; Styles, P.; Schapira, A. H.; Cooper, J. M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol., 2005, 62, 621-626.
79. Lee, S. A.; Lee, K. M.; Lee, S. J.; Yoo, K. Y.; Park, S. K.; Noh, D. Y.; Ahn, S. H.; Kang, D. Antioxidant vitamins intake, ataxia telaniectasia mutated (ATM) genetic polymorphisms, and breast cancer risk. Nutr. Cancer, 2010, 62, 1087-1094.
80. Yokota, T.; Igarashi, K.; Uchhara, T.; Jishage, K.; Tomita, H.; Inaba, A.; Li, Y.; Arita, M.; Suzuki, H.; Mizusawa, H.; Arai, H. Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl. Acad. Sci. USA, 2001, 98, 15185-15190.
81. Armstrong, J. S.; Khdour, O.; Hecht, S. M. Does oxidative stress contribute to the pathology of Friedreich's ataxia? a radical question. FASEB J., 2010, 24, 2152-2163.
82. Reichenbach, J.; Schubert, R.; Schindler, D.; Müller, K.; Böhles, H.; Zielen, S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid. Redox. Signal, 2002, 4, 465-469.
83. Reliene, R.; Schiestl, R. H. Experimental antioxidant therapy in ataxia telangiectasia. Clin. Med. Oncol., 2008, 2, 431-436.
84. Araujo, J.; Breuer, P.; Dieringer, S.; Krauss, S.; Dorn, S.; Zimmermann, K.; Pfeifer, A.; Klockgether, T.; Wuellner, U.; Evert, B. O. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum. Mol. Genet., 2011, 20, 2928-2941.
85. Seznec, H.; Simon, D.; Bouton, C.; Reutenauer, L.; Hertzog, A.; Golic, P.; Procaccio, V.; Patel, M.; Drapier, J. C.; Koenig, M.; Puccio, H. Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet., 2005, 14, 463-474.
86. Cooper, J. M.; Schapira, A. H. Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors, 2003, 18, 163-171.
87. Anderson, P. R.; Kirby, K.; Orr, W. C.; Hilliker, A. J.; Phillips, J. P. Hydrogen peroxide scavenging rescues frataxin deficiency in a Dorsophila model of Friedreich's ataxia. Proc Natl Acad Sci USA, 2008, 105, 611-616.
88. Paupe, V.; Dassa, E. P.; Goncalves, S.; Auchére, F.; Lönn, M.; Holmgren, A.; Rustin, P. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich's ataxia. PloS One, 2009, 4, e4253.
89. Kemp, K.; Mallam, E.; Hares, K.; Witherick, J.; Scolding, N.; Wilkins, A. Mesenchymal stem cells restore frataxin expression and increase hydrogen peroide scavenging enzymes in Friedreich's ataxia fibroblast. PloS One, 2011, 6, e26098.
90. Rötig, A.; Sidi, D.; Munnich, A.; Rustin, P. Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol. Med., 2002, 8, 221-224.
91. Berni, A.; Meschini, R.; Filippi, S.; Palitti, F.; de Amicis, A.; Chessa, L. L-Carnitine enhances resistance to oxidative stress by reducing DNA damage in ataxia telengiectasia cells. Mutat. Res., 2008, 650, 165-174.
92. Jauslin, M. L.; Meier, T.; Smith, R. A.; Murphy, M. P. Mitochondria targeted antioxidants protect Friedreich's ataxia fibroblast from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 2003, 17, 1972-194.
93. Schulz, J. B.; Dehmer, T.; Schöls, L.; Mende, H.; Hardt, C.; Vorgerd, M.; Bürk, K. Oxidative stress in patients with Friedreich's ataxia. Neurology, 2000, 55, 1719-1721.
94. Calabrese, V.; Lodi, R.; Tonon, C.; D'Agata, V.; Sapienza, M.; Scapagnini, G.; Mangiameli, A.; Pennisi, G.; Stella, A. M.; Butterfield, D. A. Oxidative stress, mitochondial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci., 2005, 233, 145-162.
95. Lim, C. K.; Kalonowski, D. S.; Richardson, D. R. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol. Pharmacol., 2008, 74, 225-235.
96. Jauslin, M. L.; Vertuani, S.; Durini, E.; Buzzoni, L.; Ciliberti, N.; Verdecchia, S.; Palozza, P.; Meier, T.; Manfredini, S. Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of ldebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich's ataxia. Mol. Cell. Biochem., 2007, 302, 79-85.
97. Pollard, J. M.; Reboucas, J. S.; Durazo, A.; Kos, I.; Fike, F.; Panni, M.; Gralla, E. B.; Valentine, J. S.; Batinic-Haberle, I.; Gatti, R. A. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. Free Radic. Biol. Med., 2009, 47, 250-260.
98. Fryer, M. J. Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Fridreich's ataxia. Med. Hypotheses, 2002, 58, 127-132.
99. Browne, S. E.; Roberts, L. J. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic. Biol. Med., 2004, 36, 938-942.
100. Myers, L.; Farmer, J. M.; Wilson, R. B.; Friedman, L.; Tsou, A.; Perlman, S. L.; Subramony, S. H.; Gomez, C. M.; Ashizawa, T.; Wilmot, G. R.; Mathews, K. D.; Balcer, L. J.; Lynch, D. R. Antioxidant use in Friedreich's ataxia. J. Neurol. Sci., 2008, 267, 174-176.
101. Llrens, J. V.; Navarro, J. A.; Martínez-Sebastián, M. J.; Baylies, M. K.; Schneuwly, S.; Botella, J. A.; Moltó, M. D. Causative role of oxidative stress in Drosophila model of Friedreich's ataxia. FASEB J., 2007, 21, 333-344.
102. Chantrel-Groussard, K.; Geromel, V.; Puccio, H.; Koenig, M.; Munnich, A.; Rötig, A.; Rustin, P. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet., 2001, 10, 2061-2067.
103. Sparaco, M.; Gaeta, L. M.; Santorelli, F. M.; Passarelli, C.; Tozzi, G.; Bertini, E.; Simonati, A.; Scaravilli, F.; Taroni, F.; Duyckaerts, C.; Feleppa, M.; Piemonte, F. Friedreich's ataxia: oxidative stress and cycloskeletal abnormalities. J. Neurol. Sci., 2009, 287, 111-118.
104. Shackelford, R. E.; Manuszak, R. P.; Johnson, C.D.; Hellrung, D. J.; Link, C. K.; Wang, S. Iron chelators increase the resistance of ataxia telangiectasia cells to oxidative stress. DNA Repair (Amst), 2004, 3, 1263-1272.
105. Wang, Y. C.; Lee, C. M.; Lee, L. C.; Tung, L. C.; Hsieh-Li, H. M.; Lee-Chen, G. J.; Su, M. T. Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA 12). J. Biol. Chem., 2011, 286, 21742-21754.
106. Pasichna, E. P.; Morozova, R' P.; Donchenko, H. V.; Vinychuk, S. M.; Kopchak, O. O. Lipid peroxidation and antioxidant defense enzyme activity in multiple sclerosis. Ukr. Biokhim. Zh., 2007, 79, 165-174.
107. Odinak, M. M.; Bisaga, G. N.; Zarubina, I. V. New approaches to antioxidant therapy in multiple sclerosis. Zh. Nevrol. Psikhiatr. Im. SS. Korsakova, 2002, 72-75.
108. Miller, E.; Morwicka, M.; Zołyński, K.; Kedziora, J. Oxidative stress in multiple sclerosis. Pol. Merkur. Lakarski., 2009, 27, 499-502.
109. Krotenko, N. V.; Alifieova, V. M.; Ivanova, S. A. Parameters of antioxidant protection in multiple sclerosis. Zh. Nevrol. Psikhiatr. Im. SS. Korsakova, 2009, 109, 53-56.
110. Bisaga, G. N.; Odinak, M. M.; Boǐko, A. N.; Meľnik, LuB.; Popova, N. F. Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy. Zh. Nevrol. Psikhiatr. Im. SS. Korsakova, 2011, 111, 44-48.
111. Weatherby, S. J.; Mann, C. L.; Davies, M. B.; Fryer, A. A.; Haq, N.; Strange, R. C.; Hawkins, C. P. A pilot study of the relationship between gadolinium-enhancing lesions, gender effect and polymorphisms of antioxidant enzymes in multiple sclerosis. J. Neurol., 2000, 247, 467-470.
112. Mirshafiey, A.; Mohsenzadegan, M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol., 2009, 31, 13-29.
113. Liu, Y.; Zhu, B.; Wang, X.; Luo, L.; Li, P.; Patty, D. W.; Cynader, M. S. Bilirubin as potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol., 2003,139, 27-35.
114. Besler, H. T.; Comoǧlu, S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr. Neurosci., 2003, 6, 189-196.
115. Koch, M.; Ramsaransing, G. S.; Arutjunyan, A. V.; Stepanov, M.; Teelken, A.; Heersema, D. J.; De Keyser, J. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J. Neurol., 2006, 253, 483-487.
116. Mossberg, N.; Movtz, C.; Hellstrand, K.; Bergström, T.; Nilsson, S.; Anderson, O. Oxygen radical production in leukocytes and disease severity in multiple sclerosis. J. Neuroimmunol., 2009, 213, 131-134.
117. Lucas, M.; Rodríguez, M. C.; Gata, J. M.; Zayas, M. D.; Solano, F.; Izquierdo, G. Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem. Int., 2003, 42, 67-71.
118. Ghabaee, M.; Jabedari, B.; Al-E-Eshagh, N.; Ghaffarpour, M.; Asadi, F. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int. J. Neurosci., 2010, 120, 301-304.
119. Besler, H. T.; Comoǧlu, S.; Okçu, Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr. Neurosci., 2002, 5, 215-220.
120. Hadžović-Džuvo, A.; Lepara, O.; Valjevac, A.; Avdagić, N.; Hasić, S.; Kiseljaković, E.; Ibragić, S.; Alajbegović, A. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn. J. Basic Med. Sci., 2011, 11, 33-36.
121. van Horssen, J.; Schreibelt, G.; Drexhage, J.; Hazes, T.; Dijkstra, C. D.; van der Valk, P.; de Vries, H. E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med., 2008, 45, 1729-1737.
122. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol., 2004, 251, 261-268.
123. Schreibelt, G.; van Horssen, J.; van Rossum, S.; Dijkstra, C. D.; Drukarch, B.; de Vries, H. E. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res. Rev., 2007, 56, 322-330.
124. Berbecki, J.; Mitosek-Szewczyk, K.; Kurzepa, J.; Nastaj, M.; Łobejko, K.; Stelmasiak, Z. Processes of free radical lipid peroxidation with a particular regard to the role of paraoxonase-1 in the pathogenesis of multiple sclerosis. Wiad. Lek., 1960, 64, 31-36.
125. Bishop, A.; Hobbs, K. G.; Eguchi, A.; Jeffrey, S.; Smallwood, L.; Pennie, C.; Anderson, J.; Estévez, A. G. Differential sensitivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis. J. Neurochem., 2009, 109, 93-104.
126. Lev, N.; Ickowicz, D.; Barham, Y.; Blondheim, N.; Melamed, E.; Offen, D. Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis. Antioxid. Redox. Signal, 2006, 8, 1987-1995.
127. Mitosek-Szewczyk, K.; Gordon-Krajcer, W.; Walendzik, P.; Stelmasiak, Z. Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia. Neuropathol., 2010, 48, 116-122.
128. Reese, D.; Shivapour, E. T.; Wahls, T. L.; Dudley-Javoroski, S. D.; Shields, R. Neuromuscular electrical stimulation and dietary interventions to reduce oxidative stress in a secondary progressive multiple sclerosis patient leads to marked gains in function: a case report. Cases J., 2009, 2, 7601.
129. Gonsette, R. E. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci., 2008, 274, 48-53.
130. Ortiz, G. G.; Macías-Islas, M. A.; Pacheco-Moisés, F. P.; Cruz-Ramos, J. A.; Sustersik, S,; Barba, E. A.; Aguayo, A. Oxidative stress is increased in serum from Mexican patients with relapsingremitting multiple sclerosis. Dis. Markers, 2009, 26, 35-39.
131. Jana, A.; Pahan, K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J. Neuroimmune Pharmacol., 2007, 2, 184-193.
132. Koch, M.; Mostert, J.; Aeutjunyan, A.; Steoanov, M.; Teelken, A.; Heersema, D.; De Keyser, J. Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis. Mult. Scler., 2007, 14, 159-165.
133. Witherick, J.; Wilkins, A.; Scolding, N.; Kemp, K. Mechanism of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmun. Dis., 2011, 164608. doi.10.406/2011/64608.
134. Gonsette, R. E. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult. Scler., 2008, 14, 22-34.
135. Gold, R.; Wolinsky J. S.; Armato, M. P.; Giancarlo, S. Evolving expectations around early management of multiple sclerosis. Ther. Adv. Neurol. Disord., 2010, 3, 351-367.
136. Chiurchiu, V.; Maccarrone, M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxd. Redox. Signal, 2011,15, 2605-2641.
137. Singh, I.; Pahan, K.; Khan, M.; Singh, A. K. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J. Biol. Chem., 1998, 273, 20354-20362.
138. Antony, J. M.; van Marle, G.; Opii, W.; Butterfield, D. A.; Mallet, F.; Yong, V.W.; Wallace, J. L.; Deacon, R. M.; Warren, K.; Power, C. Human endogenous retrovirous glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci., 2004, 7, 1088-1095.
139. Calabrese, V.; Boyd-Kimball, D.; Scapagnini, G.; Butterfield, D. A. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo, 2004, 18, 245-267.
140. Song, W.; Su, H.; Song, S.; Paudel, H. K.; Schipper, H. M. Overexpression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J. Cell. Physiol., 2006, 206, 655-663.
141. Wang, J.; Dore, S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain, 2007, 130, 1643-1652.
142. Krone, B.; Grange, J. M. Paradigms in multiple sclerosis: time for a change, time for a unifying concept. Inflammopharmacology, 2011, 19, 187-195.
143. Bella, R.; Milone, P.; Ventimiglia, B.; Migliore, M. R.; Di Renzo, L.; De Lorenzo, A.; Calabrese, V. Redox regulation of cellular stress response in multiple sclerosis. Biochem. Pharmacol., 2011, 82, 1490-1499.
144. Di Giuseppe, D.; Ulivelli, M.; Bartalini, S.; Battistini, S.; Cerase, A.; Passero, S.; Summa, D.; Frosali, S.; Priora, R.; Margaritis, A.; Di Simplicio, P. Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids, 2010, 38, 1461-1471.
145. Tasset, I.; Sánchez, F.; Túnez, I. The molecular bases of Huntington's disease: the role played by oxidative stress. Rev. Neurol., 2009, 49, 424-429.
146. Li, X.; Valencia, A.; Sapp, E.; Masso, N.; Alexander, J.; Reeves, P.; Kegel, K. B.; Aronin, N.; Difiglia, M. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J. Neurosci., 2010, 30, 4552-4561.
147. Butterfiel, D. A.; Howard, B. J.; LaFontaine, M. A. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr. Med. Chem., 2001, 8, 815-828.
148. Pérez-Severiano, F.; Santamaría, A.; Pedraza-Chaverri, J.; Medina-Campos, O. N.; Ríos, C.; Segovia, J. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase acivity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem. Res., 2004, 29, 729-733.
149. Chen, C. M. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Ned. J., 2011, 34, 135-152.
150. Duran, R.; Barrero, F. J.; Morales, B.; Luna, J. D.; Ramirez, M.; Vives, F. (2010) Oxidative stress and plasma aminopeptidase activity in Huntington's disease. J. Neural. Transm., 2010, 117, 325-332.
151. del Hoyo, P.; García-Redondo, A.; de Bustos, F.; Molina, J. A.; Sayed, Y.; Alonso-Navarro, H.; Caballero, L.; Arenas, J.; Jiménez, F. J. (2006) Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem. Res., 2006, 31, 1103-1109.
152. Klepac, N.; Relja, M.; Klepac, R.; Hećimović, S.; Babić, T.; Trkulja, V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects; a cross-sectional study. J. Neurol., 2007, 254, 1676-1683.
153. Stoy, N.; Mackay, G. M.; Forrest, C.M.; Christofides, J.; Egerton, M.; Stone, T. W.; Darlington, L. G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem., 2005, 93, 611-623.
154. Fontaine, M. A.; Geddes, J. W.; Banks, A.; Butterfield, D.A. Effect of exogenous and endogenous antioxidants on 3-nitropionic acidinduced in vivo oxidative stress and striatal lesions: insight into Huntington's disease. J. Neurochem., 2000, 75, 1709-1715.
155. Túnez, I.; Sánchez-López, F.; Agüera, E.; Fernández-Bolańos, R.; Sánchez, F. M.; Tasset-Cuevas, I. Important role of oxidative stress biomarkers in Huntington's disease. J. Med. Chem., 2011, 54, 5602-5206.
156. Túnez, I.; Montilla, P.; Del Carmen Muńoz, M.; Feijóo, M.; Salcedo, M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res., 2004, 37, 252-256.
157. Velichkovskiǐ, B. T. Free radical oxidation as a link of early and prolonged adaptation to environmental factors. Vestn. Ross. Akad. Med. Nauk., 2001, 45-52.
158. Kumagai, S.; Jikimoto, T.; Saegusa, J. Pathological roles of oxidative stress in autoimmune diseases. Rinsho. Byori., 2003, 51, 126-132.
159. Goncharova, N. D.; Marenin Vlu Oganian, T. E.; Shamliǐ, A. V.; Bogatyrenko, T. N.; Kozina, L. S.; Prokopenko, V. M. Stress, aging, hypothalamic-pituitary-adrenal axis and reliability of antioxidant enzyme defense. Adv. Gerontol., 2008, 21, 548-554.
160. Rosety-Rodriguez, M.; Ordonez, F. J.; Rosety, I.; Frias, L.; Rosety, M. A.; Rosety, J. M, Rosety, M. 8-Weeks training program attenuates mitochondrial oxidative stress in the liver of emotionally stressed rats. Histol. Histopathol., 2006, 21, 1167-1170.
161. Mayorov, D. N. Brain superoxide as a key regulator of the cardiovascular response to emotional stress in rabbits. Exp. Physiol., 2007, 92, 471-479.
162. Rahman, M. M.; Ishiyanagi, T.; Komiyama, T.; Sato, S.; Konishi, T. Effects of anthocyanins on psychological stress-induced oxidative stress and neurotransmitter status. J. Agric. Food Chem., 2008, 56, 7545-7550.
163. Kuchukashvili, Z.; Menabde, K.; Chachua, M.; Burjanadze, G.; Chipashvili, M.; Koshoridze, N. Functional state of rat cardiomyocytes and blood antioxidant system under psychoemotional stress. Acta Biochim. Biophys. Sin., (Shanghai), 2011, 43, 480-486.
164. De Luca, C.; Deeva, I.; Mariani, S.; Maiani, G.; Stancato, A.; Korkina, L. Monotoring antioxidant defense and free radical production in space-flight, aviation and railway engine operators, for the prevention and treatment of oxidative stress, immunological impairment, and pre-mature cell aging. Toxicol. Ind. Health, 2009, 25, 259-267.
165. Bouayed, J.; Rammal, H.; Soulimani, R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid. Med. Cell Longev., 2009, 2, 63-67.
166. Goncharova, N. D.; Marenin, V.Y.; Bogatryrenko, T.N. Stress, aging and reliability of antioxidant enzyme defense. Curr. Aging Sci., 2008, 1, 22-29.
167. Carrí. M. T.; Ferri, A.; Cozzolino, M.; Calabrese, L.; Rotili, G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res. Bull., 2003, 61, 365-374.
168. Larrode, P.; Iñarrea, P.; Capablo, J. L.; Iñiguez, C.; Ara, J. R.; Martin, J.; Mostacero, E. Mitochondrial superoxide dismutase activity in amyotrophic lateral sclerosis. Open Spine J., 2009, 1, 5-8.
169. Kirkinezos, I. G.; Bacman, S. R.; Hernandez, D.; Oca-Cossio, J.; Arias, L. J.; Perez-Pinzon, M. A.; Bradley, W. G.; Moraes, C. T. Cytochrome c association with inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J. Neurosci., 2005, 25, 164-172.
170. Jung, C.; Rong, Y.; Doctrow, S.; Baudry, M.; Malfroy, B.; Xu, Z. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett., 2001, 304, 157-160.
171. Shin, J. H.; Cho, S. I.; Lim, H. R.; Lee, J. K.; Lee, Y. A.; Noh, J. S.; Joo, I. S.; Kim, K-W.; Gwag, B. J. Concurrent administration of Neu2000 and lithium produces marked improvement in motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol. Pharmacol., 2007, 71, 965-975.
172. Farooqui, A. A.; Ong, W-Y.; Horrocks, L. A. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurological disorders. Pharmacol. Rev., 2006, 58, 591-620.
173. Watt, N. T.; Taylor, D. R.; Gillott, A.; Thomas, D. A.; Perera, W. S.; Hooper, N. M. Reactive oxygen species-mediated ß-cleavage of the prion protein in the cellular response to oxidative stress. J. Biol. Chem., 2005, 280, 35914-35921.
174. An, R.; Dong, C. F.; Lei, Y. J.; Li, P.; Chen, J. M.; Wang, G. R.; Shi, Q.; Gao, C.; Jiang, H. Y.; Zhou, W.; Han. J.; Chu, Y. L.; Dong, X. P. PrP mutants with different numbers of octarepeat sequence are more susceptible to the oxidative stress. Sci. China. Ser. C-Life Sci., 2008, 51, 630-639.
175. Sakudo, A.; Ikuta, K. Fundamentals of prion disease and their involvement in the loss of function of cellular prion proteins. Protein Peptide Lett., 2009, 16, 217-229.
176. Lo, R. Y-Y.; Shyu, W-C.; Lin, S-Z.; Wang, H-J.; Chen, S-S.; Li, H. New molecular insights into cellular survival and stress responses: neuroprotective role of cellular prion protein (PrPc). Mol. Neurobiol., 2007, 35, 236-244.
177. Lohr, J. B.; Kuczenski, R.; Niculescu, A. B. Oxidative mechanisms and Tardive Dyskinesis. CNS Drugs, 2003, 17, 47-62.
178. Al Hadithy, A. F. Y.; Ivanova, S. A.; Pechlivanoglou, P.; Wilffert, B.; Semke, A.; Fedorenko, O.; Kornetova, E.; Rysdovaya, L.; Brouwers, J. R. B. J.; Loonen, A. J. M. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum. Psychpharmacol. Clin. Exp., 2010, 25, 84-91.
179. Zai, C. C.; Tiwari, A. K.; Basile, V.; de Luca, V.; Müller, D. J.; Voineskos, A. N.; Remington, G.; Meltzer, H. Y.; Lieberman, J. A.; Potkin, S. G.; Kennedy, J. L. Oxidative stress in Tardive Dyskinesis: genetic association study and meta-analysis of NADPH quinone oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog. Neuropsychpharmacol. Biol. Psychiatry, 2010, 34, 50-56.
180. Baker, P.R.; van Harten, P. N.; van Os, J. Antipsychotic-induced Tardive Dyskinesis and polymorphic variations in COMT, DRD2, CVYP1A2 and MnSOD genes: meta-analysis of pharmacogenetic interactions antipsychotic-induced TD in COMT, DRD2, CYP1A2 and MnSOD genes. Mol. Psychiatry, 2008, 13, 544-556.
181. Pham, D. Q.; Pharm, D.; Plakogiannis, R.; Pharm, D. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, Tardive Dyskinesis, and cataract: part 2. Ann. Pharmacotherp., 2005, 39, 2065-2071.
182. Busanello, A.; Barbosa, N. B. V.; Peroza, L. R.; Farias, L. E.; Burger, M. E.; Barreto, K. P.; Fachinetto, R. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav. Pharmacol., 2011, 22, 71-75.
183. Thaakur, S.; Himabindhu, G. Effect of alpha lipoic acid on the Tardive Dyskinesis and oxidative stress induced by haloperidol in rats. J. Neural. Transm., 2009, 116, 807-814.
184. Naidu, P. S.; Singh, A.; Kulkarini, S. K. Quercetin, a bisflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology, 2003, 44, 1100-1106.
185. Shukla, V.; Mishra, S. K.; Pant, H. Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci., 2011, 572634.
186. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J. Free radical and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
187. Marlatt, M.; Lee, H-G.; Perry, G.; Smith, M. A.; Zhu, X. Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta. Neurobiol. Exp., 2004, 64, 81-87.
188. Butterfield, D. A.; Perluigi, M.; Sultana, R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol., 2006, 545, 39-50.
189. Chang, Y.; Kong, Q.; Shan, X.; Tian, G.; Ilieva, H.; Cleveland, D. W.; Rothstein, J. D.; Borchelt, D. R.; Wong, P. C.; Lin, C-L. G. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS ONE, 2008, 3, e2849.
190. Pogocki, D. Alzheimer's ß-amyloid peptide source of neurotoxic free radicals: the role of structural effects. Acta. Neurobiol. Exp., 2003, 63, 145.
191. Gella, A.; Durany, N. Special focus: molecular and cellular events controlling neuronal and brain function and dysfunction. Cell Adhesion Migr., 2009, 3, 83-93.
192. Hamel, E.; Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Tong, XK. Oxidative stress and cerebrovascular dysfunction in mouse model Alzheimer's disease. Exp. Physiol., 2007, 93, 116-120.
193. Axelson, P. H.; Komatsu, H.; Murray, I. V. J. Oxidative stress and cell membrane in the pathogenesis of Alzheimer's disease. Physiology, 2011, 26, 54-69.
194. Williams, W. M.; Weinberg, A.; Smith, M. A. Protein modification by dicarbonyl molecular species in neurodegenerative disease. J. Amino Acids, 2011, 461216.
195. Aliev, G.; Palacios, H. H.; Gasimov, E.; Obrenovich, M. E.; Morales, L.; Leszak, J.; Bragin, V.; Herrera, A. S.; Gokhman, D. Oxidative stress induced mitochondrial failure and vascular hyperfusion as a key initiator for the development of Alzheimer's disease. Pharmaceuticals, 2010, 3, 158-187.
196. Massaad, C. A.; Pautler, R. G.; Klann, E. Mitochondrial superoxide a key player in Alzheimer's disease. Aging, 2009, 9, 758-761.
197. Parihar, M. S.; Brewer, G. J. Microenergetic failure in Alzheimer's disease. Am. J. Physiol. Cell Physiol., 2007, 292, C8-C23.
198. Sesti, F.; Liu, S.; Cai, S-Q. Oxidation of potassium channels by ROS; a general mechanism of aging and neurodegeneration. Trends Cell Biol., 2009, 20, 45-51.
199. Bondy, S. Nanopartocles and colloids as contributing factors in neurodegenerative disease. Int. J. Environ. Res. Public Health, 2011, 8, 2200-2211.
200. Salminen, A.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K,.; Ojala, J. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J. Neuroinflammation, 2009, 6, 41.
201. Uttara, B.; Singh, A. V.; Zamoni, P.; Mahajan, R. T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol., 2009, 7, 65-74.
202. Hashim, A.; Wang, L.; Juneja, K.; Ye, Y.; Zhao, Y.; Ming, L-J. Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related CuII-ß-amyloid complexes-cooperative action of phosphor-moiety. Bioor. Med. Chem. Lett., 2011, 21, 6430-6432.
203. Mates, J. M.; Segura, J. A.; Alonso, F. J.; Marquez, J. Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. Free Radic. Biol. Med., 2010, 49, 1328-1341.
204. Aliev, G.; Li, Y.; Palacios, H. H.; Obrenovich, M. E. Oxidative stress induced mitochondrial DNA deletion as hallmark for the drug development in the context of the cerebrovascular diseases. Rec. Pat. Cardiovasc. Drug Discov., 2011, 6, 222-241.
205. Dumont, M.; Beal, M. F. Neuroprotective strategies involving ROS in Alzheimer's disease. Free Radic. Biol. Med., 2011, 51, 1014-1026.
206. Chonpathompikunlert, P.; Yoshitomi, T.; Han, J.; Toh, K.; Hiroko, I.; Nagasaki, Y. Chemical nanotherapy: nitroxyl radical-containing nanoparticles protect neuroblastoma SH-SY5Y cells from Aßinduced oxidative stress. Ther. Deliv., 2011, 2, 585-597.
207. Numakawa, T.; Matsumoto, T.; Numakawa, Y.; Richards, M.; Yamawaki, S.; Kunugi, H. Protective action of neurotrophic factors and estrogen against oxidative stress-mediated neurodegeneraion. J. Toxicol., 2011, 405194. doi:10.1155/2011/405194
208. Moreira, P. I.; Harris, P. L. R.; Zhu, X.; Santos, M. S.; Oliveira, C.R.; Smith, M. A.; Perry, G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer's disease patient fibroblasts. J. Alzheimer's Dis., 2007, 12, 195-206.
209. Lee, H. P.; Zhu, X.; Casadesus, G.; Castellani, R. J.; Nunomura, A.; Smith, M. A.; Lee, H-G.; Perry, G. Antioxidant approaches for the treatment of Alzheimer's disease. Exp. Rev. Neurotherap., 2010, 10, 1201-1208.
210. Nelson, V. M.; Dancik, C. M.; Pan, W.; Jiang, Z. G.; Lebowit, M. S.; Ghanbari, H. A. Pan-811 inhibits oxidative stress-induced cell death of human Alzheimer's disese-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J. Alzheimer's Dis., 2009, 17, 611-619.
211. Farooqui, T.; Farooqui, A. A. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Res. Parkinson's Dis., 2011, 247467.
212. Nikam, S.; Nikam, P.; Ahaley, S. K.; Sontakke, A. V. Oxidative stress in Parkinson's disease. Ind. J. Clin. Biochem., 2009, 24, 98-101.
213. Fridlich, A. L.; Smith, M. A.; Zhu, X.; Takeda, A.; Nunomura, A.; Moreira, P. I.; Perry, G. Oxidative stress in Parkinson's disease. Open Pathol. J., 2009, 3, 38-42.
214. Olivieri, S.; Conti, A.; Iannaccone, S.; Cannistraci, C. V.; Campanella, A.; Barbariga, M.; Codazzi, F.; Pelizzoni, I.; Magnani, G.; Pesca, M.; Franciotta, D.; Cappa, S. F.; Alessio, M. Ceruloplamin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J. Neurosci., 2011, 31, 18568-18577.
215. Mot, A. I.; Wedd, A. G.; Sinclair, L.; Brown, D. R.; Collins, S. J.; Brazier, M. W. Parkinson's disease-Review, metal attenuating therapies in neurodegenerative disease. Exp. Rev. Neurotherap., 2011, 11, 1717-1745.
216. Kapfenbauer, K.; Yoo, B. C.; Fountoulakis, M.; Mitrova, E.; Lube, G. Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. Electrophoresis, 2002, 23, 2541-2547.
217. Gonatas, N. K.; Stieber, A.; Gonatas, J. O. Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. J. Neurol. Sci., 2006, 246, 21-30.
218. Kell, D. B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's. prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol., 2010, 84,825-889.
219. Kovacic, P.; Somanathan, R. Unifying mechanism for metals in toxicity, carcinogenicity and therapeutic action: integrated approach involving electron transfer, oxidative stress, antioxidants, cell signaling and receptors. J. Recept. Signal Transduct., 2010, 30, 51-60.